DE02733871T1 - Synergistische kombinationen von retinoid-rezeptor-liganden und ausgewählte zytotoxische mittel zur krebsbehandlung - Google Patents

Synergistische kombinationen von retinoid-rezeptor-liganden und ausgewählte zytotoxische mittel zur krebsbehandlung Download PDF

Info

Publication number
DE02733871T1
DE02733871T1 DE0001383491T DE02733871T DE02733871T1 DE 02733871 T1 DE02733871 T1 DE 02733871T1 DE 0001383491 T DE0001383491 T DE 0001383491T DE 02733871 T DE02733871 T DE 02733871T DE 02733871 T1 DE02733871 T1 DE 02733871T1
Authority
DE
Germany
Prior art keywords
rarα
cytotoxic agent
cytotoxic
selective
rar pan
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
DE0001383491T
Other languages
German (de)
English (en)
Inventor
Sandrine Valerie VIVAT-HANNAH
V. Matthew LORENZI
M. Marco GOTTARDIS
Christopher Fred ZUSI
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Bristol Myers Squibb Co
Original Assignee
Bristol Myers Squibb Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bristol Myers Squibb Co filed Critical Bristol Myers Squibb Co
Publication of DE02733871T1 publication Critical patent/DE02733871T1/de
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
DE0001383491T 2001-03-22 2002-03-22 Synergistische kombinationen von retinoid-rezeptor-liganden und ausgewählte zytotoxische mittel zur krebsbehandlung Pending DE02733871T1 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US27775401P 2001-03-22 2001-03-22
US277754P 2001-03-22
PCT/US2002/008718 WO2002078620A2 (en) 2001-03-22 2002-03-22 Synergistic combinations of retinoid receptor ligands and selected cytotoxic agents for treatment of cancer

Publications (1)

Publication Number Publication Date
DE02733871T1 true DE02733871T1 (de) 2004-08-26

Family

ID=23062213

Family Applications (1)

Application Number Title Priority Date Filing Date
DE0001383491T Pending DE02733871T1 (de) 2001-03-22 2002-03-22 Synergistische kombinationen von retinoid-rezeptor-liganden und ausgewählte zytotoxische mittel zur krebsbehandlung

Country Status (15)

Country Link
EP (1) EP1383491A2 (es)
JP (1) JP2004528316A (es)
KR (1) KR20030086314A (es)
CN (1) CN1498105A (es)
BR (1) BR0207681A (es)
CA (1) CA2441335A1 (es)
CZ (1) CZ20032540A3 (es)
DE (1) DE02733871T1 (es)
ES (1) ES2214985T1 (es)
HU (1) HUP0400255A2 (es)
IL (1) IL157358A0 (es)
MX (1) MXPA03008403A (es)
PL (1) PL368946A1 (es)
TR (1) TR200400812T3 (es)
WO (1) WO2002078620A2 (es)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2395401T3 (es) * 2006-03-23 2013-02-12 Tmrc Co., Ltd. kit para la terapia del cáncer y composición farmacéutica para la terapia del cáncer

Also Published As

Publication number Publication date
TR200400812T3 (tr) 2004-07-21
CA2441335A1 (en) 2002-10-10
CZ20032540A3 (cs) 2004-05-12
KR20030086314A (ko) 2003-11-07
WO2002078620A2 (en) 2002-10-10
JP2004528316A (ja) 2004-09-16
IL157358A0 (en) 2004-02-19
MXPA03008403A (es) 2004-01-29
ES2214985T1 (es) 2004-10-01
EP1383491A2 (en) 2004-01-28
PL368946A1 (en) 2005-04-04
WO2002078620A3 (en) 2003-04-17
CN1498105A (zh) 2004-05-19
BR0207681A (pt) 2004-07-27
HUP0400255A2 (hu) 2004-08-30

Similar Documents

Publication Publication Date Title
Bowles et al. Evaluation of new gingival retraction agents
WO2021050953A8 (en) Compositions and methods for the delivery of therapeutic biologics for treatment of disease
HRP20230272T1 (hr) Postupci za liječenje cistične fibroze
CA2528160A1 (en) Use of 1-(3,4-dimethoxyphenethyl)-4-(3-phenylpropyl) piperazine for neuronal regeneration and functional recovery
JP2008519047A5 (es)
JP2015512406A5 (es)
RU2008119454A (ru) Лекарственное средство для защиты моторного нейрона у пациентов с боковым амиотрофическим склерозом
WO2000002542A2 (de) Mittel mit antidepressiver wirkung, enthaltend pramipexol und ein weiteres antidepressivum
HRP20140215T1 (hr) Kombinacija koja sadrži paklitaksel za lijeäśenje raka jajnika
JP2019517587A5 (es)
JP2019508476A5 (es)
RU2010151660A (ru) Способы лечения множественной миеломы
JP2012526090A (ja) Ａｖｅ８０６２およびソラフェニブを含む抗腫瘍の組み合わせ
JP2015522077A5 (es)
JP5680412B2 (ja) レオヌリンの使用およびその組成物
JP2005500298A5 (es)
HRP20230300T1 (hr) Kombinacije imetelstata i venetoklaksa za liječenje akutne mijeloidne leukemije
DE02733871T1 (de) Synergistische kombinationen von retinoid-rezeptor-liganden und ausgewählte zytotoxische mittel zur krebsbehandlung
WO2021022058A3 (en) Antiarrhythmic formulation
Gardner et al. Treatment of pulps of monkeys with vancomycin and calcium hydroxide
RU99119233A (ru) Фармацевтические композиции, содержащие ибупрофен и домперидон для лечения мигрени
WO2014176417A1 (en) Topical preparation for bypassing gi tract, delivery of therapeutics, and trans-epithelial drug delivery system
Velíšek et al. Estrogen Treatment Protects GABAB Inhibition in the Dentate Gyrus of Female Rats after Kainic Acid–Induced Status Epilepticus
SA522441056B1 (ar) مُركّب جديد من كبريتات [2-(داي ميثيل أمينو)-2-فينيل بيوتيل]-3، 4، 5-تراي ميثوكسي بنزوات 4-ميثيل-2h-كرومين-2-ون-7-يل واستخدامه
JP2005513167A5 (es)